Therapy prediction in lung cancer

Vilde Drageset Haakensen, Project group leader
Vilde Drageset Haakensen, Project group leader

Lung cancer is the leading cause of cancer-related death. Treatment efficacy is currently limited by lack of robust predictive biomarkers to select the best treatment for an individual patient, therapy resistance and low availability of targeted therapies. To identify new predictive biomarkers and achieve better stratification of patients, we collect biological material and imaging data. Integrated analysis of profiling of primary tumour, gut microbiome, circulating markers and imaging markers are used to characterise patients and tumour diseases. The new knowledge and procedures will be used to enhance treatment and design new clinical trials.

Current projects

  1. Molecular characterisation of lung squamous cell carcinomas 
  2. Translational studies related to ongoing clinical trials:
    Clinical trials:
    1.  DART - Durvalumab After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients
    2. NIPU - Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Translational projects:
    1. Gut microbiome profiling to identify alterations during immunotherapy and identify biomarkers for therapy response
    2. Immune cell profiling of tumour and circulating body fluids to study immune response to therapy and identify predictive biomarkes.
    3. Evaluation of dual PET to elucidate tumour cell composition in response to therapy 
  3. National PI of clinical trials:
    a. PACIFIC-R
    b. M7824 with cCRT in Unresectable Stage III NSCLC
    c. KeyNote-012 (A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
  4. Local PI of clinical trials: 
    a. NARLAL2 (Novel Approach to Radio Therapy in Locally Advanced Lung Cancer)
    b. KeyNote-867 (A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)
  5. Main supervisor for Hanne Marte Nymoen, Saim Jamil Farooqi and a PhD student to start in December 2021, co-supervisor for Henrik Horndalsveen